Efficacy and safety of eltrombopag in the treatment of Chinese children with chronic immune thrombocytopenia.

Eltrombopag not only shows excellent initial response but also has continued efficacy and safety. Patients with megakaryocyte count ≥100/slide and Treg<4.5% achieve increased initial response and more frequent durable response.